Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon

Study: Delaying delivery may improve post-Norwood neurologic outcomes

Previous reports have linked Norwood patients to neurodevelopment impairment. Now, a study published online March 28 in Circulation has shown that neurodevelopment impairment in these patients may be associated with innate patient factors and morbidity in the first year rather than intraoperative management strategies.

JAMA: LDL-C may not be best target for statin treatment

Non-high-density lipoprotein cholesterol (non-HDL-C) was more strongly associated with future cardiovascular risk than low-density lipoprotein cholesterol (LDL-C) in patients taking statins, suggesting that the former may be a better target for statin treatment, according to a study published March 28 in the Journal of the American Medical Association.

ACC: Newer anticoagulants may reduce medical costs compared with warfarin

CHICAGOThe usage of dabigatran, rivaroxban and apixaban may be associated with a reduction in medical costs when used instead of warfarinwith apixaban potentially being associated with the greatest cost reduction, based on an analysis of ARISTOTLE, RE-LY and ROCKET-AF trials, presented March 26 at the 61st annual American College of Cardiology (ACC) scientific session.

ACC: Novel therapy lowers LDL-C by 72%

CHICAGO--A novel monoclonal antibody lowered low density lipoprotein cholesterol (LDL-C) up to 72 percent in patients with primary hypercholesterolemia in a randomized, double-blind, placebo-controlled trial. The results were announced March 26 at the  61st annual American College of Cardiology scientific session and simultaneously published online in the Journal of the American College of Cardiology.

ACC: Is rivaroxaban the new EINSTEIN for VTE?

CHICAGOAs more and more anticoagulants continue to seep into research and onto the market as alternatives to warfarin, a late-breaking clinical trial presented March 26 at the 61st annual American College of Cardiology (ACC) scientific session showed rivaroxaban to be noninferior to enoxaparin for patients with venous thromboembolism (VTE). The drug was also shown to result in less intracranial bleeds.

ACC: Triple-antiplatelet therapy is non-inferior to double-dose of dual antiplatelets

CHICAGOA popular three-pronged drug approach in Asia that adds chilostazol to dual antiplatelet therapy had comparable outcomes to a double-dose dual antiplatelet regimen, according to the results of the late-breaking HOST-ASSURE clinical trial presented March 25 at the 61st annual American College of Cardiology (ACC) scientific session.

ACC: Angiomax+ReoPro reduces infarct size, but Angiomax+aspiration thrombectomy does not

CHICAGOIn patients with large anterior STEMI presenting early after symptom onset and undergoing primary PCI with bivalirudin (Angiomax, The Medicines Company) anticoagulation, infarct size at 30 days was significantly reduced by bolus intracoronary abciximab (ReoPro, Eli Lilly) delivered to the infarct lesion site but not by manual aspiration thrombectomy, according to INFUSE-AMI, a late-breaking clinical trial presented March 25 at the 61st annual American College of Cardiologys (ACC) scientific session.

ACC: When should devices or drugs stop being used in practice?

CHICAGOWhen medical drugs or devices begin to go awry, does the company know beforehand about the potential issues? This is the question Steve E. Nissen, MD, chairman of the department of cardiovascular medicine at the Cleveland Clinic, asked March 24 at the 61st annual American College of Cardiology (ACC) scientific session. The presentation aimed to answer one question: When should devices or medicines stop being used in practice?

Displaying 1689 - 1696 of 2350

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.